Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents, specifically, dacarbazine, cis-platinum, tamoxifen and interferon-alfa.
<PROLEUKIN, effect, antineoplastic agents>, <PROLEUKIN, effect, dacarbazine>, <PROLEUKIN, effect, cis-platinum>, <PROLEUKIN, effect, tamoxifen>, <PROLEUKIN, effect, interferon-alfa>